1. Home
  2. FT vs MOLN Comparison

FT vs MOLN Comparison

Compare FT & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Universal Trust

FT

Franklin Universal Trust

HOLD

Current Price

$8.12

Market Cap

199.8M

Sector

Finance

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

N/A

Current Price

$4.10

Market Cap

144.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
FT
MOLN
Founded
1988
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
199.8M
144.0M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
FT
MOLN
Price
$8.12
$4.10
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$8.38
AVG Volume (30 Days)
32.5K
3.5K
Earning Date
01-01-0001
05-14-2026
Dividend Yield
7.85%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$318.52
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.83
$3.36
52 Week High
$8.35
$5.36

Technical Indicators

Market Signals
Indicator
FT
MOLN
Relative Strength Index (RSI) 53.59 41.81
Support Level $7.82 $4.04
Resistance Level $8.24 $4.51
Average True Range (ATR) 0.10 0.17
MACD 0.02 -0.04
Stochastic Oscillator 70.86 35.65

Price Performance

Historical Comparison
FT
MOLN

About FT Franklin Universal Trust

Franklin Universal Trust is a closed-end management investment company focused on providing high current income while preserving capital. Its secondary objective is to achieve income growth through dividend increases and capital appreciation. The fund invests in two asset classes: high-yield bonds and utility stocks. It applies fundamental research to build a diversified high-yield bond portfolio and targets utility companies with attractive dividend yields and a history of increasing dividends.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.

Share on Social Networks: